◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Dr. Reddy’s Laboratories Ltd ADR (RDY) EBITDA 2007–TTM

Name: Dr. Reddy’s Laboratories Ltd ADR (RDY) ebitda history 2007-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-29

Dr. Reddy’s Laboratories Ltd ADR annual ebitda for fiscal TTM was INR 55.6 billion, a decrease of 33.3% from INR 83.3 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

RDY Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31
EBITDA	INR 55.6B	INR 83.3B	INR 96.7B	INR 88.4B	INR 74.4B	INR 45.1B	INR 535M	INR 41.8B	INR 35.5B	INR 23.6B	INR 24.8B	INR 39.9B	INR 34.4B	INR 33.1B	INR 22.5B	INR 20.3B	INR 16.8B	INR 6.6B	INR 1.5B	INR 7.3B	INR 14.3B

INR; INRM / INRB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RDY Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
EBITDA	INR 3.0B	INR 8.8B	INR 19.6B	INR 24.3B	INR 24.6B	INR 25.3B	INR 24.3B	INR 23.9B

INR; INRM / INRB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

UTHR EBITDA — United Therapeutics Corporation
NBIX EBITDA — Neurocrine Biosciences Inc
ELAN EBITDA — Elanco Animal Health
ALKS EBITDA — Alkermes Plc
HIMS EBITDA — Hims Hers Health Inc

More RDY metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All RDY financial statements → Interactive RDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.